Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Hematology, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 60 - 75 |
Updated: | 2/21/2019 |
Start Date: | March 27, 2018 |
End Date: | March 2020 |
Contact: | Denise Correa, PhD |
Email: | corread@mskcc.org |
Phone: | 212-610-0491 |
The purpose of this study is to learn about possible changes in thinking (cognitive)
abilities, such as memory skills, and in brain anatomy and function, in adults with multiple
myeloma who are treated with high-dose chemotherapy followed by ASCT.
abilities, such as memory skills, and in brain anatomy and function, in adults with multiple
myeloma who are treated with high-dose chemotherapy followed by ASCT.
Inclusion Criteria:
- Diagnosed with multiple myeloma and in complete, partial or very good partial
remission at enrollment as per standard International Myeloma Working Group Criteria
- Scheduled to have high-dose chemotherapy and ASCT
- Age 60 - 75 years at study entry
- In the judgment of the consenting professional, fluent and able to communicate well
enough in English to complete the study assessments and provide informed consent.
- Patients who report that English is not their primary language will be asked the
US Census English proficiency question "How well do you speak English" and the
answer "very well" will be required
Exclusion Criteria:
- With signs and/or symptoms of central nervous system cancers (e.g., tumors,
metastases, leptomeningial disease) as determined by their physician, medical records,
or by a brain MRI, either at the time of enrollment or during the study period
- With current diagnosis of major Axis I psychiatric disorder (DSM-IV), major
depression, bipolar disorder, or schizophrenia, as per medical records or patient
report
- As per patient report or as confirmed by the medical record, if the patient is taking
anti-depression or anti-anxiety medication, < 2 months on these medications or a
change in the prescribed dose in the past 2 months
- With history of a neurological disorder, neurodegenerative disease, or traumatic brain
injury with loss of consciousness (>60 minutes), as per medical records or patient
report
- With a history of another cancer, except for non-melanoma skin cancer, as per medical
records or patient report
- With current substance abuse and/or history of substance abuse, as per medical records
or patient report
- With evidence of visual or auditory impairment that would preclude completion of the
assessments, as per medical records or patient report
- With contraindications to MRI examinations as per standard screening guidelines used
in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers
or defibrillators, stents, claustrophobia)
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Denise Correa, MD
Phone: 212-610-0491
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials